Navigation Links
Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/5/2009

may raise issues that must be resolved prior to obtaining final approval of the NDA; the risk that increased attention to drug safety issues in general may result in a more cautious approach by the FDA, which could delay the completion of the review process for the Acetavance NDA, or result in limitations in the indications for use or the inclusion of unfavorable information in the labeling for this product candidate; intense competition from existing and new products, which could diminish the commercial potential for Acetavance; the possibility that the patent rights covering Acetavance may not be sufficient to preclude other intravenous formulations of acetaminophen from being developed by competitors; the potential for Cadence to require substantial additional funding in order to obtain regulatory approval for and commercialize Acetavance, and the risk that the company may not be able to raise sufficient capital when needed, or at all; and other risks detailed in Cadence's prior press releases as well as in Cadence's periodic public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Cadence(TM) and Acetavance(TM) are trademarks of Cadence Pharmaceuticals, Inc.

    Contact:  William R. LaRue
              SVP & Chief Financial Officer
              Cadence Pharmaceuticals, Inc.
              858-436-1400

                            CADENCE PHARMACEUTICALS, INC.
                            (a develop
'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
3. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
5. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
6. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
7. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... PA & Boston, MA (PRWEB) July 28, 2014 ... collaboration agreements with two researchers to further develop potential ... deadly malignant brain tumor, in combination with their patented ... by ITI and Duke University, are based on the ... Chief, Division of Neurosurgery at The Preston Robert Tisch ...
(Date:7/28/2014)... , July 28, 2014  InterMune, Inc. (NASDAQ: ... release its second quarter 2014 financial results at the ... 2014. A live conference call and webcast will be hosted ... day. Interested investors and others may participate ... +1 212-231-2900 (international), conference ID#21728775. A replay of the webcast ...
(Date:7/25/2014)... (PRWEB) July 26, 2014 "Ischemic ... H2, 2014" provides data on the Ischemic Stroke ... provides elemental information and data relating to the ... , View full global Ischemic Stroke Research Report ... an overview of the trial numbers and their ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 According to ... "Biological Drugs Market - Global Industry Analysis, Size, Share, ... biological drugs market is estimated at USD 161,056.5 million ... CAGR of 10.1% from 2014 to 2020, to reach ... , The biological drugs market is witnessing a significant ...
Breaking Biology Technology:String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4InterMune to Release Second Quarter Financial Results on August 6 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3
... as I sat at lunch sending off a series of ... how our professional lives continue to evolve dramatically, and in ... of a company that is driving the adoption of Internet ... quickly technological change continues to transform and enhance our professional ...
... action. Lies do not become us." , ,- Dread Pirate ... sometime seem like a big challenge to marketers. They can ... opportunity, however, small business owners can also be timely and ... and growing market to many businesses. According to the ...
... building of a state-of-the-art medical research facility that could ... new drug candidates is being challenged by a vocal ... in Chandler, Ariz., the proposed facility represents the next ... Inc. , following the recent expansion of its facilities ...
Cached Biology Technology:Visions: Rimas Buinevicius, CEO of Sonic Foundry 2Visions: Rimas Buinevicius, CEO of Sonic Foundry 3Big opportunities with small businesses 2Big opportunities with small businesses 3Covance spars with animal rights activists 2Covance spars with animal rights activists 3Covance spars with animal rights activists 4
(Date:7/28/2014)... cities that have seen an increase in so-called "nuisance ... overwhelmed storm drains and compromised infrastructure--are on the East ... This nuisance flooding, caused by rising sea levels, has ... 925 percent since the 1960s. , The report, Sea ... United States, also finds Annapolis and Baltimore, Maryland, lead ...
(Date:7/28/2014)... St. Jude Children,s Research Hospital study found that 73 ... doubled their risk of developing metabolic syndrome and related ... The results appear in the current issue of the ... the 1,598 adult survivors of childhood cancer in the ... risk factors like high blood pressure, abdominal obesity, elevated ...
(Date:7/28/2014)... natural virus killers to prevent and treat HIV infection ... inflammatory response these molecules can arouse as they get ... scientists at the Weizmann Institute and the National Institutes ... of these molecules interferons around the time ... of the disease. Their research appeared in Nature ...
Breaking Biology News(10 mins):NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3Interfering with interferon 2
... Md., Aug. 31 The Lockheed Martin (NYSE: LMT ... has successfully completed Critical Design Review (CDR) for the system,s fingerprint ... Bureau of Investigation,s (FBI) new multi-modal, state-of-the-art biometrics system. , ... the quantum leap in capability that NGI will deliver as a ...
... chunks of red meat: when wildlife specialists find these ... can now use newly published genetic sequences known as ... hope that this simple technique will track the harvesting ... and Central America, and Africa) and will ultimately crack ...
... matter, has been used by commercial growers and amateur ... is added to potting soil to help retain moisture ... grew, acres of peat bogs were being drained and ... peat from wetlands are mounting. And as peat supplies ...
Cached Biology News:Lockheed Martin Team Completes Key Design Milestone on Federal Bureau of Investigation's Next Generation Identification Program 2The first DNA barcodes of commonly traded bushmeat are published 2The first DNA barcodes of commonly traded bushmeat are published 3For peat's sake: Alternative growing media 2
L1 Protein of Human Papilloma Virus Purified Anti-Viral-transformed cells clone CAMVIR-1, Isotype Mouse IgG 2a , 0.1 mg Consult technical datasheet for details....
... g. High quality kits and ... that give consistent and reliable ... tissues.Clean up samples from contaminants.Efficiently ... quantitate protein for first-dimension isoelectric ...
... The Varian Cary 50 ... reduces your cost per analysis ... throughput of the award-winning Cary ... analyze up to 384 samples ...
GOAT ANTI CARICA PAPAYA PAPAIN...
Biology Products: